Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield^TM®) and BBV-152 (Covaxin^TM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study.

ABSTRACT:

Background

We assessed the humoral immune response of both ChAdOx1-nCOV (Covishield^TM) and BBV-152 (Covaxin^TM) vaccines in Indian health care workers (HCW).

Methods

A Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study was conducted that measured SARS-CoV-2 anti-spike binding antibody quantitatively, 21 days or more after the first and second dose of two vaccines in both severe acute respiratory syndrome (SARS-CoV-2) naïve and recovered HCW. Primary aim was to analyze antibody response (seropositivity rate, Geometric Mean Titre [GMT] and 95% Confidence Interval [CI]) following each dose of both vaccines and its correlation to age, sex, blood group, body mass index (BMI) and comorbidities. Here we report the results of an

SUBMITTER: Singh AK 

PROVIDER: S-EPMC8461292 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature